A NOVEL CD16+ NATURAL KILLER CELL AND A METHOD OF CULTURING CD16+ NATURAL KILLER CELL

The present invention provides a human CD16+ natural killer cell line. This human CD16+ natural killer cell line does not include synthetic, genetically modified or deliberately delivered polynucleotide encoding the CD16 receptor and is a non-tumorigenic cell line. Therefore, this human CD16+ natura...

Full description

Saved in:
Bibliographic Details
Main Authors Lee, Chia-Yun, Lin, Yan-Liang, Yang, Hsiu-Ping, Li, Hao-Kang, Lai, Yan-Da, Hsiao, Ching-Wen, Hsiao, Shih-Chia, Cheng, Zih-Fei, Cheng, Yu-Pei
Format Patent
LanguageEnglish
Published 10.03.2022
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present invention provides a human CD16+ natural killer cell line. This human CD16+ natural killer cell line does not include synthetic, genetically modified or deliberately delivered polynucleotide encoding the CD16 receptor and is a non-tumorigenic cell line. Therefore, this human CD16+ natural killer cell line might provide considerable long-term safety for disease treatment.
Bibliography:Application Number: US202017423044